Financial Overview

• Cash received in Lilly collaboration $110 M

  • Upfront payments - $80M
  • Equity purchased - $30M ($18.69/share)

• Cash expenditures for 3Q 2002: $26 M

• Cash at end of 3Q 2002: $180 M

• Estimated cash burn for 4Q 2002: >$30 M

Previous slide

Next slide

Back to first slide

View graphic version